Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
Phase 4
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Digaoxin,amiodarone,β receptor antagonist, Calcium AntagonistsProcedure: catheter ablation
- Registration Number
- NCT01341353
- Lead Sponsor
- Wuhan University
- Brief Summary
The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1800
Inclusion Criteria
- 1 Patients with symptomatic AF recorded by ECG or Holter 2 Age:18-75 years 3 Patients who are willing to enroll in the trial
Exclusion Criteria
- 1 Patients accompanied hyperthyroidism 2 Patients with sever liver or renal dysfunction 3 Patients with sever cardiac dysfunction 4 Patients had previous radiofrequency catheter ablation in the LA or Maze surgical procedure 5 Patients with emboli in atrium 6 Pregnant woman
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Antiarrythmic Drugs Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists - ablation catheter ablation -
- Primary Outcome Measures
Name Time Method Number of participants with all-cause death 36 month severe blooding complications 36 month cardio-cerebrovascular complications 36 month Number of participants with cardiovascular death events 36 month
- Secondary Outcome Measures
Name Time Method recurrence of atrial arrhythmias (AF, AFL, AT) 36 month resource utilization and costs 36 month
Trial Locations
- Locations (1)
Renmin Hospital of Wuhan University
🇨🇳Wuhan, Hubei, China